



## Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery

Authors: [Men-Jean Lee, MD](#), [Debra Guinn, MD, FACOG](#)

Section Editors: [Charles J Lockwood, MD, MHCM](#), [Richard Martin, MD](#)

Deputy Editor: [Vanessa A Barss, MD, FACOG](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

**Literature review current through:** Jan 2018. | **This topic last updated:** Jan 23, 2018.

**INTRODUCTION** — In a landmark paper, Liggins and Howie showed that a single course of antenatal corticosteroid therapy administered to women at risk for preterm delivery (PTD) reduced the incidence and severity of respiratory distress syndrome (RDS) and mortality in offspring [1]. Over two dozen randomized trials have confirmed these findings [2]. Subsequent trials have also shown that antenatal corticosteroid therapy improves circulatory stability in preterm neonates, resulting in lower rates of intraventricular hemorrhage (IVH) and necrotizing enterocolitis compared with unexposed preterm neonates.

This topic will review evidence supporting the use of antenatal corticosteroids to improve neonatal outcomes in women at risk for preterm delivery, pharmacological issues, and clinical concerns about administration of this therapy.

### BACKGROUND

**Mechanism of action** — Corticosteroid stimulation of developmentally regulated gene expression and physiologic functions result in maturation of the lungs and some other tissues [3]. Antenatal steroids accelerate development of type 1 and type 2 pneumocytes, leading to structural and biochemical changes that improve both lung mechanics (maximal lung volume, compliance) and gas exchange [4-8]. Induction of type 2 pneumocytes increases surfactant production by inducing production of surfactant proteins and enzymes necessary for phospholipid synthesis. Other effects of antenatal corticosteroids include induction of pulmonary beta-receptors, which play a role in surfactant release and absorption of alveolar fluid when stimulated [5]; induction of fetal lung antioxidant enzymes [9]; and upregulation of gene expression for the epithelial Na<sup>+</sup> channel, which is important for absorption of lung fluid after birth [10]. For these changes to occur, however, the lungs need to have reached a stage of development that is biologically responsive to corticosteroids. (See '[Gestational age at administration](#)' below.)

The biologic rationale for repeating antenatal corticosteroid therapy is based upon the observation that biochemical stimulation of surfactant production appears to be reversible in cell culture models (eg, surfactant protein mRNA levels decline to control levels after cortisol is removed) [5,11]. However, other beneficial effects, such as cytostructural maturation, persist (in rhesus monkeys) after steroid exposure is withdrawn [12]. (See '[Use of repeated courses of therapy](#)' below.)

### Evidence of short-term clinical efficacy

**Reduction of RDS** — Randomized trials performed worldwide have consistently reported a significant reduction in the incidence of RDS among infants exposed to antenatal corticosteroid therapy. In a 2017 systematic review of randomized trials comparing antenatal corticosteroid therapy versus placebo/no treatment in women at risk for preterm birth, antenatal corticosteroid therapy resulted in a [2]:

- Reduction in RDS (relative risk [RR] 0.66, 95% CI 0.56-0.77; 28 trials, 7764 infants)
- Reduction in moderate to severe RDS (RR 0.59, 95% CI 0.38-0.91; 6 trials, 1686 infants)
- Reduction in need for mechanical ventilation (RR 0.68, 95% CI 0.56-0.84; 9 trials, 1368 infants)

A previous meta-analysis reported a statistical benefit among infants born between one and seven days after the first treatment dose (RR 0.46, 95% CI 0.35-0.60; 9 trials, 1110 infants), but not for those born less than 24 hours or more than seven days after the first dose [13]. This outcome was not evaluated in the 2017 analysis.

The benefits of corticosteroids do not appear to be affected by fetal sex [2] or race [14]; however, these conclusions are based on analysis of subgroups defined after randomization and intervention, which may have biased the results.

Despite the reduction in RDS, no significant reduction in chronic lung disease was noted (RR 0.86, 95% CI 0.42-1.79; 6 trials, 818 infants) [2].

**Reduction of IVH, NEC, NNM, infection** — Other benefits of antenatal corticosteroid therapy demonstrated by the 2017 systematic review of randomized trials include reductions in the risk of [2]:

- Intraventricular hemorrhage (IVH) (RR 0.55, 95% CI 0.40-0.76; 16 trials, 6083 infants)
- Necrotizing enterocolitis (NEC) (RR 0.50, 95% CI 0.32-0.78; 10 trials, 4602 infants)
- Neonatal mortality (NNM) (RR 0.69, 95% CI 0.59-0.81; 22 trials, 7188 infants)
- Systemic infection in the first 48 hours of life (RR 0.60, 95% CI 0.41-0.88; 8 trials, 1753 infants)

Some of these benefits derive from the beneficial effect on respiratory morbidity; however, maturational effects in numerous tissues due to corticosteroid stimulation of developmentally regulated genes and physiological function suggest an independent effect, as well [15,16].

## GESTATIONAL AGE AT ADMINISTRATION

**23+0 to 33+6 weeks** — We recommend administration of antenatal corticosteroids for all pregnant women at 23+0 to 33+6 weeks of gestation who are at increased risk of preterm delivery within the next seven days. Selection of pregnancies at increased risk of preterm delivery within the next seven days is a clinical judgment based on high probability of induction/cesarean for obstetrical or medical indications (eg, preeclampsia) or high probability of spontaneous preterm labor and delivery (eg, preterm premature rupture of membranes, tocolysis for active preterm labor).

A 2017 meta-analysis of 20 randomized trials of antenatal corticosteroids in women at risk of preterm birth provided strong evidence that respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and neonatal death are significantly reduced when corticosteroids are given before 34+0 or 35+0 weeks of gestation [2]. A lower gestational age threshold could not be assessed.

A 2016 meta-analysis of randomized trials of antenatal corticosteroid therapy before 24 weeks of gestation demonstrated a reduction in perinatal mortality at 23 weeks of gestation (OR 0.45, 95% CI 0.33-0.60), and a possible reduction at 22 weeks (OR 0.66, 95% CI 0.40-1.07) [17]. No statistical reductions were observed for respiratory distress syndrome, severe intraventricular hemorrhage, or necrotizing enterocolitis at <24 weeks. The possibility of a modest reduction cannot be definitively excluded since the number of exposed newborns and events were small. Subsequent data from a large prospective observational study of outcomes in extremely premature infants showed a clear survival benefit at 23 to 27 weeks and a beneficial trend at 22 weeks [18].

**22+6 weeks or less** — Administration of antenatal steroids at 22+0 to 22+6 weeks of gestation is reasonable if delivery in the next seven days is anticipated and the family desires aggressive neonatal intervention after

thorough consultation with maternal-fetal medicine and neonatology specialists [19]. Parents should be informed that antenatal corticosteroids may provide a survival benefit while increasing the risk for survival with severe impairment. Also, if the pregnancy is not delivered, then a single repeat course of antenatal corticosteroids may be needed later in gestation. (See "[Perivable birth \(Limit of viability\)](#)" and "[Use of repeated courses of therapy](#)" below.).

Administration of antenatal corticosteroids before 22+0 weeks of gestation is unlikely to significantly improve lung function, as there are only a few primitive alveoli at this gestational age on which the drug can exert an effect (see "[Mechanism of action](#)" above) [20].

**34+0 or more weeks** — The use of antenatal corticosteroids at  $\geq 34+0$  weeks of gestation is controversial because of inconsistent data about its efficacy and virtually no data about long-term safety. Limitations of available data are largely related to the low risk for severe respiratory morbidity after 34 weeks of gestation and lack of information on long-term outcomes after exposure to corticosteroids in late gestation [21-25]. (See "[Potential adverse effects on infants](#)" below and "[Potential long-term effects in children and adults](#)" below.)

**Our approach** — Based on the data described below, the authors take the following approach, which limits late preterm in utero steroid exposure to pregnancies certain to deliver preterm and with neonates at most risk for experiencing serious respiratory problems from transient tachypnea of the newborn. This is a controversial area and our approach differs somewhat from recommendations published by ACOG, SMFM, and RCOG, which are described below (see "[Other approaches](#)" below).

- For women scheduled for cesarean delivery at  $\geq 37+0$  weeks, we prefer not to administer a course of steroids. We inform women who have not received a prior course of steroids that the overall risk of neonatal respiratory illness at this gestational age is low and rarely serious; however, steroid administration at least 48 hours prior to delivery may reduce neonatal respiratory morbidity and length of stay. We also discuss our concerns about possible long-term risks of steroid administration at term. After this discussion, some women may choose to receive a course of steroids before their scheduled cesarean delivery.
- For women scheduled for cesarean delivery at 34+0 to 36+6 weeks, we believe offering a first course of antenatal corticosteroids to reduce neonatal respiratory morbidity is reasonable. While there may be short-term advantages to receiving steroids prior to cesarean at this gestational age, the long-term risk-to-benefit ratio is unknown. Families should be informed and participate in the decision-making.

We would not administer a second course of steroids at this gestational age to women who received steroids before 34+0 weeks as the benefits and risks have not been studied in this population.

- For women in whom vaginal delivery at  $\geq 34+0$  weeks is expected, we would not administer a first course of steroids as respiratory problems are less common after labor and vaginal birth [26-28], and we are concerned about the potential long-term risk to short-term benefit ratio.
- For women in whom delivery at 34+0 to 36+6 is uncertain (eg, threatened preterm labor), we would not administer a course of steroids because of the potential for long-term harm with no benefit if the patient does not deliver preterm.

**37+0 to 39+6 weeks of gestation** — A 2016 meta-analysis of three randomized trials of antenatal corticosteroids ([betamethasone](#) or [dexamethasone](#)) administered 48 hours before planned cesarean delivery at  $\geq 37$  weeks of gestation found reductions in neonatal respiratory morbidity compared with placebo or no treatment: transient tachypnea of the newborn (3 versus 7 percent; RR 0.38, 95% CI 0.25-0.57), respiratory distress syndrome (2.7 versus 6.7 percent; RR 0.40, 95% CI 0.27-0.59), use of mechanical ventilation (0.7 versus 3.6 percent; RR 0.19, 95% CI 0.08-0.43), as well as reductions in time on oxygen, maximum inspired oxygen, and length of stay in the NICU [29]. Neonatal hypoglycemia and long-term outcomes in offspring

were not reported. Of note, the upper gestational age at randomization in the three trials was not defined in one trial and 38+6 and 39+6 weeks of gestation in the other two trials.

**34+0 to 36+6 weeks of gestation** — The 2016 meta-analysis described above also evaluated the efficacy of steroid administration at 34+0 to 36+6 weeks of gestation, and found statistically significant reductions in severe RDS (1.4 versus 2.3 percent; RR 0.60, 95% CI 0.24-0.98) and transient tachypnea of the newborn (8.2 versus 10.9 percent; RR 0.72, 95% CI 0.50-0.98), but not RDS overall or mechanical ventilation [29]. Steroid treatment increased the risk for neonatal hypoglycemia (22.8 versus 14.2 percent; RR 1.61, 95% CI 1.16-2.12).

The analysis was dominated by the Antenatal Late Preterm Steroids Trial (ALPS), in which women at 34+0 to 36+5 weeks of gestation at high risk for late preterm birth were randomly assigned to receive a first course of antenatal corticosteroids (two injections of [betamethasone](#) 24 hours apart) or placebo [30]. No tocolytics were administered. The primary outcome was a composite of neonatal respiratory treatment in the first 72 hours (continuous positive airway pressure [CPAP] or high-flow nasal cannula for  $\geq 2$  hours, supplemental oxygen with  $\text{FIO}_2 \geq 0.30$  for  $\geq 4$  hours, extracorporeal membrane oxygenation, or mechanical ventilation), stillbirth, or neonatal death within 72 hours of delivery. Major findings were:

- The primary outcome occurred less often in the treatment group (11.6 versus 14.4 percent; relative risk [RR] 0.80; 95% CI 0.66-0.97), and was primarily driven by reductions in CPAP and high flow nasal cannula use.
- Severe respiratory complications (CPAP or high flow nasal cannula for  $\geq 12$  hours,  $\text{FIO}_2 \geq 0.30$  for at least 24 hours), transient tachypnea of the newborn, surfactant use, and bronchopulmonary dysplasia, while infrequent in absolute terms, also occurred significantly less frequently in the treatment group.
- Neonatal hypoglycemia occurred more frequently in the treatment group (24 versus 15 percent; RR 1.60; 95% CI 1.37-1.87).
- The rates of respiratory distress syndrome (RDS) and mechanical ventilation were similar in both groups (RDS: 5.5 versus 6.4 percent with placebo; mechanical ventilation: 2.4 versus 3.1 percent with placebo).

No data are available about the long-term neurodevelopmental outcomes of children exposed to corticosteroids between 34+0 and 36+5 weeks of gestation. This is a significant concern because exponential brain growth through cell division is occurring at this time and might be inhibited by administration of corticosteroids, which might affect neurodevelopment adversely (see '[Potential long-term effects in children and adults](#)' below). In newborns, postnatal systemic glucocorticoid therapy contributes to neurodevelopmental impairment, especially cerebral palsy. (See "[Postnatal use of corticosteroids in bronchopulmonary dysplasia](#)", section on '[Long-term outcome](#)'.) Other limitations of this study are that over 25 percent of participants were under 34+6 weeks at trial entry, 40 percent of women in the [betamethasone](#) group did not receive the prespecified two doses of study medication, and more than half of the subjects delivered after 36 weeks and over 15 percent delivered at term.

**Possible risks of late preterm and term in utero exposure to exogenous steroids** — We are concerned about the potential risks of administering antenatal corticosteroids to late preterm and term gestations, based on the following lines of evidence:

- The ASTECS trial compared administration of [betamethasone](#) 48 hours before planned cesarean delivery at  $\geq 37$  weeks to usual care [21]. When follow-up was performed at 8 to 15 years of age, schools were more likely to perceive steroid-exposed children to be in the lowest achievement group compared with the control group [25]. However, objective testing of academic ability was not performed as part of the trial and results from national standardized assessments did not show statistical differences between the scores for each group.

- A surge in endogenous cortisol occurs near term when the fetus is in a critical period of brain development in preparation for parturition and transition to life ex utero [31]. High levels of 11 $\beta$ -hydroxysteroid dehydrogenase-2 in the fetal brain help to protect it from the effects of the physiological rise in endogenous cortisol, but do not protect it from maternally administered [betamethasone](#) or [dexamethasone](#) due to the resistance of these drugs to metabolism by 11 $\beta$ -HSD-2 [32]. Thus, these steroids may cause unphysiological activation of glucocorticoid receptors in the fetal brain near term.

It has been proposed that exogenous steroids may have different effects at different gestational ages due to the multiple factors that change with advancing gestational age and the complex regulation of glucocorticoid receptor-mediated responses [32].

Because the human brain grows by 35 percent, cortical volume increases by 50 percent, and 25 percent of cerebellar development occurs between 34 weeks of gestation and term [33,34], exposure to exogenous [betamethasone](#) or [dexamethasone](#) during this time period is likely to have greater adverse consequences on brain development than at any other period of development. In particular, disruption of the normal fetal environment at this critical time may lead to changes in development of the neuroendocrine system, life-long effects on endocrine, behavioral, emotional, and cognitive function, and increased risks for development of a wide range of metabolic, cardiovascular, and brain disorders in later life [35-37].

- In a study of 54 preadolescent children (age 6 to 10 years) who received a single course of [betamethasone](#) at a mean gestational age of 29.3 weeks (+/- 3 weeks), delivered at term, and matched 1:2 to term infants not exposed to antenatal corticosteroids, antenatal corticosteroid exposure was associated with significant cortical thinning, particularly the rostral anterior cingulate cortex, which is strongly associated with development of affective disorders, as well as HPA axis dysregulation [38]. However, there were no overall differences in child affective problems or in total gray matter volume.

On the other hand, a study that attempted to distinguish the direct effects of antenatal steroid treatment on general cognitive functioning from confounding influences of preterm delivery found that children born at term of women without pregnancy complications scored on average 6 to 7 IQ points higher than children born at term of women hospitalized for threatened preterm delivery, whether or not they were exposed to corticosteroids in utero [39]. This suggests that factors related to risk for preterm birth may have adverse effects and imply that a single course of antenatal steroids does not contribute to long-term cognitive deficits.

- Animal models of antenatal corticosteroid exposure consistently report adverse effects [31,40-46]. As an example, various [dexamethasone](#) dosing regimens administered to preterm macaques resulted in severe adverse effects on the brain, including significant changes in the hippocampus, neural damage in the cerebral cortical neurons, and severely retarded cerebellar growth [41,43].

We are also concerned that postnatal systemic corticosteroid therapy contributes to neurodevelopmental impairment, especially cerebral palsy. (See "[Postnatal use of corticosteroids in bronchopulmonary dysplasia](#)", section on 'Long-term outcome'.)

### Other approaches

- The Society for Maternal-Fetal Medicine Specialists recommends a two-dose course of antenatal [betamethasone](#) for women at 34+0 to 36+6 weeks of gestation at high risk for preterm birth within seven days, with the following caveats [47]:
  - For women with symptoms of preterm labor, cervical dilation should be  $\geq 3$  cm or effacement  $\geq 75$  percent before treatment and tocolysis should not be used to delay delivery for completion of the course of steroids.

- For women with potential medical/obstetric indications for early delivery, steroids should not be administered until a definite plan for delivery has been made.
- The American College of Obstetricians and Gynecologists states administration of [betamethasone](#) is recommended for women with a singleton pregnancy at 34+0 to 36+6 weeks of gestation at imminent risk of preterm birth within 7 days, with the following caveats [[48,49](#)]:
  - Antenatal corticosteroid administration should not be administered to women with chorioamnionitis.
  - Tocolysis should not be used to delay delivery in women with symptoms of preterm labor to allow administration of antenatal corticosteroids. Medically/obstetrically indicated preterm delivery should not be postponed for steroid administration.
  - Antenatal corticosteroids should not be administered if the patient has already received a course antenatal corticosteroids.
  - Newborns should be monitored for hypoglycemia.
- The NICE guideline (NG25) on preterm labor and birth recommends considering maternal corticosteroids for women between 34+0 and 35+6 weeks of gestation who are in suspected, diagnosed, or established preterm labor, are having a planned preterm birth, or have preterm prelabor rupture of membranes [[50](#)].
- However, others have cautioned against universal adoption of antenatal corticosteroids for pregnancies at risk of preterm birth at 34+0 to 36+6 weeks of gestation because it is unclear whether the short-term benefits (reduction in transient tachypnea of the newborn) clearly outweigh the risks (neonatal hypoglycemia, unknowns about long-term neurodevelopmental outcome and metabolic risks) [[51](#)].

**TIMING BEFORE DELIVERY** — Maximum efficacy appears to occur when delivery occurs two to seven days after administration of the first dose of antenatal corticosteroids. Efficacy is incomplete <24 hours from administration and appears to decline after 7 days [[52-54](#)].

Antenatal corticosteroid therapy should be administered when indicated unless impending delivery is anticipated [[15](#)]. Therapy should not be withheld if delivery is anticipated prior to completion of the two-dose course of medication. We suggest this liberal approach to treatment because the minimal interval between drug administration and delivery required to achieve neonatal benefits has not been clearly defined and the hour of delivery cannot be predicted accurately. In one study, only one-quarter of women delivered within the optimal window of after steroid administration [[1,55](#)].

Observational data suggest neonatal benefits begin to accrue within a few hours of corticosteroid administration [[56,57](#)]. Infants who received one dose of [betamethasone](#) in utero, but delivered before the second dose was given, had better outcomes than infants who did not receive any antenatal corticosteroids [[56,57](#)]. Laboratory data also support an early physiologic effect as early as 6 hours following the first injection [[58,59](#)]. One study, however, observed that a betamethasone booster appeared to increase the risk of respiratory distress syndrome and decrease intact survival rates among infants who were delivered within 1 to 24 hours [[60](#)]; this finding warrants further study.

**CHOICE OF DRUG AND INITIAL DOSE** — Both [betamethasone](#) and [dexamethasone](#) are effective for accelerating fetal lung maturity; either drug is acceptable for antenatal corticosteroid therapy. We prefer betamethasone because long-term follow-up data of fetuses exposed only to dexamethasone are limited and do not clearly demonstrate equivalence or superiority of dexamethasone over betamethasone for both short- and long-term outcomes. Use of betamethasone also requires fewer injections than use of dexamethasone.

In a meta-analysis of randomized trials comparing use of different corticosteroids in women at risk of preterm birth, no statistical differences between [dexamethasone](#) and [betamethasone](#) were observed [[2,61](#)].

A course of therapy consists of:

- [Betamethasone](#) two doses of 12 mg given intramuscularly 24 hours apart **OR**
- [Dexamethasone](#) four doses of 6 mg given intramuscularly 12 hours apart. A non-sulfite containing preparation should be used as the sulfite preservative (NNF60211) commonly used in dexamethasone preparations may be directly neurotoxic in newborns [62-65].

These steroids are preferred over other steroids because they are less extensively metabolized by the placental enzyme 11 beta-hydroxysteroid dehydrogenase type 2. At the above doses, 75 to 80 percent of available corticosteroid receptors are occupied, which should provide near-maximal induction of corticosteroid receptor-mediated response in fetal target tissues [66]. These doses result in cord blood glucocorticoid levels in the range seen with physiologic stress in the preterm neonate.

There is no convincing evidence that the beneficial fetal effects of standard doses of antenatal corticosteroids are significantly reduced in overweight women (body mass index [BMI]  $\geq 25$  kg/m<sup>2</sup>), but further study is needed [67]. In a randomized trial, maternal and cord blood [betamethasone](#) levels were similar for obese (BMI  $\geq 30$  kg/m<sup>2</sup>) and non-obese women; however, this trial did not evaluate clinical outcomes [68].

The efficacy of alternative dosing regimens is unproven and discussed below. (See '[Nonstandard dosing regimens](#)' below.)

**Betamethasone** — One milliliter of the [betamethasone](#) suspension commonly used in clinical practice is a combination of 3 mg of betamethasone [sodium phosphate](#) and 3 mg of betamethasone acetate. Betamethasone sodium phosphate is soluble so it is rapidly absorbed, while betamethasone acetate is only slightly soluble and, therefore, provides sustained activity. It is only available for intramuscular injection.

The biological half-life is 35 to 54 hours [15]. The onset and duration of action is affected by the vascularity at the injection site. Drug concentrations in cord blood are approximately 20 percent of maternal levels one hour following maternal injection [66].

**Dexamethasone** — [Dexamethasone](#) is available as dexamethasone [sodium phosphate](#), which has a rapid onset and short duration of action. Therefore, the dosing frequency for dexamethasone is shorter than that for [betamethasone](#). It is less costly and more widely available than betamethasone; only sulfite-free dexamethasone preparations should be used.

Although [dexamethasone](#) is well absorbed from the gastrointestinal tract, safety and efficacy of the oral route for fetal maturation has not been established. (See '[Oral administration of dexamethasone](#)' below.)

### Other drugs for prevention of respiratory and related morbidity

**Hydrocortisone** — [Hydrocortisone](#) is extensively metabolized by placental enzymes so relatively little active drug crosses into the fetal compartment; therefore, beneficial fetal effects may not occur. However, if both [betamethasone](#) and [dexamethasone](#) are unavailable due to drug shortages, hydrocortisone 500 mg intravenously every 12 hours for four doses has been proposed as a last resort [69,70].

In women incidentally receiving high-dose [hydrocortisone](#) for treatment of a medical disorder, a standard course of [betamethasone](#) or [dexamethasone](#), when indicated for fetal lung maturation, is recommended.

**Ineffective and unproven drugs** — In systematic reviews, prophylactic antenatal maternal administration of thyrotropin-releasing hormone (TRH) [71] or ambroxol [72] did not clearly reduce respiratory morbidity, and prophylactic antenatal maternal administration of [phenobarbital](#) [73] or vitamin K [74] did not clearly reduce periventricular hemorrhage in preterm infants.

**SAFETY AND SIDE EFFECTS OF A SINGLE COURSE THERAPY** — Administration of a single course of antenatal corticosteroid therapy (ie, two doses of [betamethasone](#) or four doses of [dexamethasone](#)) before 34+0 weeks of gestation appears to be safe for the fetus/infant and mother, but has some side effects. The

safety of administration later in pregnancy is less clear. (See '[34+0 or more weeks](#)' above and '[Potential long-term effects in children and adults](#)' below.)

### Potential fetal side effects

- **Fetal heart rate and biophysical parameters** – Administration of antenatal corticosteroids may be associated with transient fetal heart rate (FHR) and behavioral changes that typically return to baseline by four to seven days after treatment [[75,76](#)]. When a nonreassuring fetal evaluation (eg, nonreactive nonstress test [NR-NST] or low biophysical profile [BPP] score) occurs within two or three days of corticosteroid administration, the possibility of transient drug-related changes should be considered. Whether continued close fetal monitoring or delivery is preferable in this setting depends on assessment of the total clinical scenario and clinical judgment. (See "[Nonstress test and contraction stress test](#)" and "[The fetal biophysical profile](#)".)

The most consistent FHR finding is a decrease in variability on days two and three after administration [[77-81](#)]. Reduced fetal breathing and body movements can result in a lower BPP score or NR-NST [[81-84](#)]. However, this is not a consistent finding; a placebo-controlled randomized trial in humans did not report a decrease in maternal perception of fetal movements in patients who received antenatal corticosteroids [[85](#)].

FHR and behavioral changes may reflect a direct physiologic response of the brain to corticosteroids or they may be an indirect result of a transient increase in fetal vascular resistance and blood pressure, which has been demonstrated in some animal studies [[86-90](#)].

- **Doppler flow studies** – A transient improvement in umbilical artery end-diastolic flow (EDF) after antenatal corticosteroid administration has been described in 63 to 71 percent of patients participating in three studies [[91-93](#)]. The improvement began about eight hours after the first dose of [betamethasone](#) and lasted a median of three days (range 1 to 10 days). However, other studies have not observed effects on fetal blood flow velocity waveform patterns in the umbilical artery, middle cerebral artery, or ductus venosus [[83,94](#)].

However, preterm fetuses with severe early-onset growth restriction and absent or reversed EDF do not have a consistent cardiovascular response to maternal [betamethasone](#) administration. Some exhibit transient improvement of EDF, while others do not. The latter group appears to be at higher risk of severe intrauterine acidosis or death. However, these observations are based on a small number of events in two studies and need to be confirmed before a change in management of this subgroup of fetuses is considered [[93,95](#)]. (See "[Doppler ultrasound of the umbilical artery for fetal surveillance](#)".)

**Potential adverse effects on infants** — In a 2017 systematic review of randomized trials, a single course of antenatal corticosteroids did not increase the risk of any adverse infant outcome, including neonatal infection, small for gestational age infant, hypothalamic-pituitary-adrenal (HPA) function, or air leak syndrome [[2](#)]. However, further research is needed, as several studies of infants exposed to antenatal corticosteroids have observed reduced basal and stress-induced cortisol secretion in these infants [[96-100](#)].

The safety and effectiveness of steroid administration at  $\geq 34+0$  weeks is less clear. In a multifaceted intervention trial (ACT) designed to increase the use of antenatal corticosteroids in low-income and middle-income countries, increased use of steroids increased neonatal and perinatal mortality in the overall population, particularly in the late preterm and early term births. This was an unexpected and unexplained finding that may have been related, in part, to increased infectious morbidities in steroid-exposed mothers and infants [[23](#)].

**Potential long-term effects in children and adults** — More data are needed on the long-term effects of antenatal corticosteroids [[2](#)]. Most studies of children/adults exposed to a single course of antenatal corticosteroids before 34 weeks of gestation have not reported adverse effects on growth; lung function; or psychosexual, motor, cognitive, neurologic, and ophthalmologic outcomes compared with unexposed controls



[4,101,102]. However, fetal programming and its consequences remain a concern. Exposure to excess corticosteroids before birth has been postulated to contribute to development of some adult diseases [103]. Some potentially adverse cardiovascular and metabolic effects have been reported and require further study (eg, increased cortisol reactivity, increased aortic arch stiffness, increased insulin resistance, increased risk of adult hypertension) [102,104-109].

Concerns also remain regarding potential adverse effects on neurodevelopmental outcome, particularly with in utero exposure late in gestation. (See '[Possible risks of late preterm and term in utero exposure to exogenous steroids](#)' above.)

Multiple courses of steroids could accentuate potential adverse effects. (See '[Use of repeated courses of therapy](#)' below.)

**Maternal side effects** — Most pregnant women tolerate a single course of antenatal corticosteroids without difficulty. In a 2017 systematic review of randomized trials, treatment did not increase the risk of maternal death, chorioamnionitis, or endometritis [2]. Case reports have described pulmonary edema, primarily associated with combination treatment with tocolytics, especially in the setting of chorioamnionitis, fluid overload, or multiple gestation [110-112]. [Betamethasone](#) itself has low mineralocorticoid activity compared with other corticosteroids; therefore, hypertension is not a contraindication to therapy [113].

Transient hyperglycemia occurs in many women; the steroid effect begins approximately 12 hours after the first dose and may last for five days. Screening for gestational diabetes, if indicated, should be performed either before corticosteroid administration or at least five days after the first dose [114,115]. In women with diabetes, hyperglycemia can be severe if not closely monitored and treated. (See '[Pregestational diabetes mellitus: Obstetrical issues and management](#)', section on '[Antenatal glucocorticoids](#)'.)

The total leukocyte count increases by about 30 percent within 24 hours after [betamethasone](#) injection, and the lymphocyte count significantly decreases [116,117]. These changes return to baseline within three days, but may complicate the diagnosis of infection.

**USE OF REPEATED COURSES OF THERAPY** — We administer a single repeat dose of [betamethasone](#) 12 mg to pregnancies up to 34 weeks of gestation with all of the following characteristics, as we feel the benefit-to-risk ratio is most favorable in this setting:

- Clinically estimated to be at high risk of delivery within the next seven days
- Prior exposure to antenatal corticosteroids at least 14 days earlier
- Initial course of antenatal corticosteroids administered at  $\leq 28$  weeks of gestation [118]

We use a single dose rather than a two-dose course of [betamethasone](#) for repeat therapy based on indirect evidence from the Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS), which demonstrated that weekly repeat dosing with a single injection of betamethasone was effective after initial standard therapy [119]. We also have concerns about potential adverse effects of repeat corticosteroid injections (see '[Evidence of effects from repeated courses of therapy](#)' below). However, a single repeat course of therapy using the two-dose betamethasone or four-dose [dexamethasone](#) regimen is also reasonable [120] and commonly used [121,122].

The American College of Obstetricians and Gynecologists (ACOG) opine that “a single repeat course of antenatal corticosteroids should be considered in women who are less than 34+0 weeks of gestation who have an imminent risk of preterm delivery within the next 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously. Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario” [49]. In contrast to our approach, ACOG does not limit rescue steroids to women whose initial course of antenatal corticosteroids was administered at  $\leq 28$  weeks of gestation.

**Evidence of effects from repeated courses of therapy** — Evidence for repeating steroid therapy was provided by a 2015 systematic review of randomized trials that assessed the effectiveness and safety of repeated doses of antenatal [betamethasone](#) versus no repeat courses for women who remain at risk of preterm birth  $\geq 7$  days after an initial course of therapy [123]. Compared with a single course of therapy, repeated courses of betamethasone resulted in:

For the neonate:

- Reduced risk of respiratory distress syndrome (RDS) (relative risk [RR] 0.83, 95% CI 0.75-0.91, 8 trials, 3206 infants, numbers needed to treat [NNT] 17, 95% CI 11-32).
- Reduced risk of composite serious infant outcomes (RR 0.84, 95% CI 0.75-0.94, 7 trials, 5094 infants, NNT 30, 95% CI 19-79). Serious infant outcomes were variably defined in each trial and included perinatal death, bronchopulmonary dysplasia, severe intraventricular hemorrhage, necrotizing enterocolitis, sepsis, periventricular leukomalacia, and/or retinopathy of prematurity.

However, repeated dosing did not result in statistically significant reductions in risk for individual outcomes of severe lung disease (RR 0.80, 95% CI 0.56-1.14, 6 trials, 4826), perinatal mortality (RR 0.94, 95% CI 0.71-1.23, 9 trials, 5554 infants), chronic lung disease (RR 1.06, 95% CI 0.87-1.30, 8 trials, 5393 infants), or intraventricular hemorrhage (RR 0.94, 95% CI 0.75-1.18, 6 trials, 3065 infants).

- Reduction in mean birth weight (mean difference -75.79 g, 95% CI -117.63 to -33.96, 9 trials, 5626 infants), which was not statistically significant when birthweight was adjusted for gestational age.

For the mother:

- No significant increase in chorioamnionitis (RR 1.16, 95% CI 0.92-1.46, 6 trials, 4261 women)
- No significant increase in puerperal sepsis (RR 1.15, 95% CI 0.83-1.60, 5 trials, 3091 women)

For the young child:

- No significant harm or benefit. At follow-up in early childhood (18 months to two years corrected age), there were no statistically significant differences in total deaths; survival free of any disability or major disability; major disability; composite serious outcome; growth assessment (weight, height); developmental delay; blindness; deafness; or cerebral palsy. The ACTORDS follow-up group confirmed these findings and lack of effect on bone mass at six to eight years of age [124,125].

However, we and others [100] remain concerned about administering multiple repeat courses of steroid therapy because the systematic review did not evaluate whether there was an increased risk of harm as the number of repeat courses of [betamethasone](#) increased. Individual trials suggest increasing exposure to steroids is associated with increasing risk of adverse effect:

- In the Maternal Fetal Medicine Units network (MFMU) trial, 63 percent of patients received  $\geq 4$  courses of therapy. The percentage of small for gestational age (SGA) fetuses below the 10th percentile and below the 5th percentile was significantly higher in the repeated steroid course group compared with the single course group (for the 10th percentile: 19.3 versus 8.4 percent; for the 5th percentile 10.4 versus 4.7 percent) [126]. After 32 weeks of gestation, placental weight was significantly less in the repeat corticosteroid group and was related inversely to the number of steroid courses [127]. Although statistically nonsignificant, repeat courses were associated with an increased incidence of cerebral palsy (one case of cerebral palsy in the control group and five in the weekly steroid group; RR 5.68, 95% CI 0.69-46.7); five of the six children with cerebral palsy were delivered near term or term and five of the six were exposed to  $\geq 4$  courses of antenatal corticosteroids [126].
- A secondary analysis of data from the Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study, a randomized trial of single versus multiple course steroid therapy, reported a dose-response

relationship between the number of corticosteroid courses and a decrease in fetal growth [128]. Multiple courses of therapy were not associated with an increased risk of maternal side effects [129] or the composite outcome of death/survival with a neurodevelopmental disability at five years of age [130].

- In a small prospective cohort study, exposure to repeat courses of antenatal corticosteroids appeared to impact some aspects of executive functioning, but was not associated with general deficits in higher cognitive functions, self-reported attention, adaptability, or overall psychological function [131].

Other experimental evidence from human and animal studies also supports a link between prenatal exposure to synthetic glucocorticoids and alterations in fetal development that may be permanent [31,132-135].

**Evidence for salvage, rescue, booster therapy** — Use of a single repeat course of antenatal corticosteroids has been termed salvage, rescue, or booster therapy. Salvage (rescue, booster) therapy is an attractive alternative to routinely repeating weekly courses of antenatal corticosteroids once an initial course has been given. Salvage (rescue, booster) therapy is limited to pregnancies estimated to be at high risk of delivering within seven days. In theory, this would allow a single booster or rescue course of therapy to those pregnancies most likely to benefit. This could result in a reduction in RDS without increasing the risk of potentially adverse outcomes.

Three placebo-controlled randomized trials of salvage (rescue, booster) therapy have been published. One trial (n = 249 pregnancies) did not show a reduction in the incidence of RDS with salvage therapy (52 percent with [betamethasone](#) versus 48 percent with placebo) [60], while the other (n = 437 pregnancies) reported a significant reduction in RDS (41.4 percent [67/162] with betamethasone versus 61.6 percent [101/164] with placebo; OR 0.45, 95% CI 0.27-0.75) [121]. A higher proportion of subjects that actually received the intervention in the second trial compared with the first trial likely accounted for the significant reduction in RDS. A third placebo-controlled randomized trial (n = 85 pregnancies) also suggested a benefit: a rescue course of betamethasone significantly increased respiratory compliance (primary outcome) and, in deliveries less than 34 weeks, significantly decreased the incidence of RDS (15/44 [34 percent] versus 22/39 [56 percent] in the placebo group) [122]. When deliveries at all gestational ages were included, the reduction in RDS remained but was not statistically significant (15/56 [27 percent] versus 23/56 [41 percent]).

Although none of these trials reported a statistical increased risk of adverse effects, no firm conclusions can be made since the number of subjects and events was small and the infants were followed for only a short time after birth.

**NONSTANDARD DOSING REGIMENS** — There is no convincing evidence of the safety and efficacy of increasing the steroid dose, accelerating the dosing interval, or using an intravenous or oral route of administration.

**Higher dose** — In a clinical study, doubling the dose of [betamethasone](#) to 24 mg per day was not associated with increased efficacy [136].

Pharmacokinetic studies demonstrated that the standard dosing intervals of two 12 mg doses of [betamethasone](#) administered 24 hours apart provide maximum glucocorticoid receptor occupancy and near-maximal stimulation of glucocorticoid receptor target genes in fetal tissues [5,137,138]. If receptors are not available for activation, then a higher daily dose of glucocorticoid would not be expected to increase efficacy and the excess drug would likely be excreted. In addition, supraphysiological doses of glucocorticoids suppress glucocorticoid receptor levels by “homologous down-regulation” [139]. Thus, administration of a higher dose of steroid would probably result in no more than a negligible increase in fetal lung maturation.

**Shorter dosing interval** — Shortening the dosing interval has been proposed to increase the probability of completing the steroid course before delivery. The safety and effectiveness of this approach are unclear as it is supported by limited low-quality evidence [140,141], and one of these studies reported a possible increased risk of necrotizing enterocolitis with a shorter dosing interval, which is concerning [140]. Therefore,

a shortened dosing interval should be avoided until data from appropriately powered randomized trials demonstrate efficacy and safety.

**Intravenous administration** — The clinical efficacy of intravenous antenatal corticosteroids has not been studied in human pregnancy. Intravenous administration results in rapid peaks and troughs in maternal and fetal steroid concentrations. This produces less sustained fetal exposure to corticosteroid stimulation and thus may not be as effective as intramuscular administration.

**Oral administration of dexamethasone** — In the absence of adequate data establishing the safety and efficacy of oral [dexamethasone](#) therapy for fetal maturation, we recommend using only intramuscular therapy.

Outpatient oral administration of [dexamethasone](#) has been used to facilitate completion of full courses of corticosteroids in ambulatory women at increased risk of preterm delivery. In the only randomized trial of this approach, 170 women between 24 and 33 weeks of gestation at high risk of preterm delivery were randomly assigned to receive either 6 mg intramuscular dexamethasone or 8 mg oral dexamethasone every 12 hours for 4 doses, repeated weekly until 34 weeks [142]. There was no statistical difference between groups in the frequency of RDS, but the oral dexamethasone group had significantly higher rates of intraventricular hemorrhage (IVH) and neonatal sepsis, leading to premature discontinuation of the trial after 39 percent enrollment.

**TESTING FOR FETAL LUNG MATURITY AFTER ANTENATAL CORTICOSTEROID THERAPY** — We recommend not performing tests for fetal lung maturation following antenatal corticosteroid therapy because these tests may not be sufficiently sensitive to detect subtle changes in the surfactant concentration of amniotic fluid. In addition, they cannot assess the effects of steroid-induced architectural changes of the fetal lung.

Although some studies have reported an increased lecithin-sphingomyelin ratio or TDx-FLM II five days to two weeks after corticosteroid therapy [143-145], several other series found no change in this ratio [1,146,147]. (See "[Assessment of fetal lung maturity](#)".)

## SPECIAL POPULATIONS

**Multiple gestation** — We use a standard dosing schedule for both singleton and multiple gestations.

In a 2017 systematic review, the small number of multiple gestations included in the antenatal corticosteroid trials precluded a definite conclusion about the effectiveness of the therapy or the optimum dose (respiratory distress syndrome [RDS] in multiple gestations exposed to antenatal steroids: relative risk [RR] 0.90, 95% CI 0.67-1.22; 4 trials, 320 infants) [2]. In theory, multiple gestations may require higher doses of antenatal corticosteroids to maximize fetal exposure. However, maternal and cord blood [betamethasone](#) levels were similar in singleton and multiple gestations in a randomized trial [68]. This trial did not compare clinical outcomes. A prospective pharmacokinetic study also reported pharmacokinetics were the same for singleton and multiple gestations [148].

Observational data suggest benefits in multiple gestations exposed to antenatal corticosteroids, although these studies have not consistently reported a statistical benefit or the benefits achieved in singletons [149-153].

ACOG recommends consideration of a single repeat course of antenatal corticosteroids in pregnancies <34 weeks that have an imminent risk of preterm delivery within the next seven days and had a prior course of antenatal corticosteroids >14 days previously [154]. They also state that rescue-course corticosteroids could be provided as early as seven days from the prior dose, if indicated by the clinical scenario.

**Hypertension** — [Betamethasone](#) has low mineralocorticoid activity compared with other corticosteroids and does not aggravate hypertension. A meta-analysis of five small randomized trials supported both the safety and efficacy (reduction in RDS) of antenatal corticosteroid therapy in pregnancies complicated by hypertension [2].

**Diabetes** — Antenatal corticosteroid therapy should be administered to women with diabetes when indicated; however, hyperglycemia related to corticosteroid administration can be severe in this population if not closely monitored and treated. The steroid effect on glucose levels begins approximately 12 hours after the first dose and may last for five days. Women with diabetes generally have been excluded from randomized trials of antenatal corticosteroid therapy because of the adverse effects of steroids on glycemic control, thus efficacy in this population is inferred [155]. (See "[Pregestational diabetes mellitus: Obstetrical issues and management](#)", [section on 'Antenatal glucocorticoids'](#).)

**Preterm premature rupture of membranes** — Antenatal corticosteroid administration improves neonatal outcome in pregnancies complicated by preterm premature rupture of membranes and does not increase the risk of neonatal or maternal infection. (See "[Preterm prelabor rupture of membranes](#)", [section on 'Administration of antenatal corticosteroids'](#).)

**POSTNATAL SURFACTANT THERAPY** — Postnatal surfactant administration is not a substitute for antenatal corticosteroid therapy. The combination of antenatal corticosteroid therapy and postnatal exogenous surfactant reduces neonatal morbidity and mortality more than use of exogenous surfactant alone [156]. A 2017 meta-analysis that evaluated data from trials before and after the widespread use of surfactant concluded that antenatal corticosteroids appeared to be beneficial in the era of advanced neonatal practice [2].

## SUMMARY AND RECOMMENDATIONS

- Antenatal corticosteroid therapy leads to improvement in neonatal lung function by enhancing maturational changes in lung architecture and by inducing lung enzymes involved in respiratory function. (See "[Mechanism of action](#)" above.)
- Antenatal corticosteroid therapy reduces the incidence of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, and neonatal mortality by approximately 50 percent. These effects are not limited by gender or race; efficacy in multiple gestations is unclear, as high-quality data are sparse. (See "[Evidence of short-term clinical efficacy](#)" above and "[Multiple gestation](#)" above.)
- Given these benefits, we recommend administration of antenatal corticosteroids to pregnant woman who are at 23+0 to 33+6 weeks of gestation and at increased risk of preterm delivery within the next seven days (**Grade 1A**). In our practice, we restrict administration of the first course of antenatal corticosteroids to women who rupture membranes or are receiving tocolysis for active preterm labor, or in whom delivery for maternal or fetal indications is anticipated within the next seven days. This approach minimizes the need for salvage (rescue, booster) therapy while allowing most patients to receive a course of antenatal corticosteroids prior to preterm delivery.

A course of antenatal corticosteroids consists of [betamethasone](#) suspension 12 mg intramuscularly every 24 hours for two doses **or** four doses of 6 mg [dexamethasone](#) intramuscularly 12 hours apart. We prefer betamethasone over dexamethasone. (See "[Choice of drug and initial dose](#)" above.)

- Observational data suggest neonatal benefits begin to accrue within a few hours of corticosteroid administration. Maximum efficacy appears to occur when delivery occurs two to seven days after administration of the first dose of antenatal corticosteroids. Efficacy is incomplete <24 hours from administration and appears to decline after 7 days. (See "[Timing before delivery](#)" above.)
- We consider approximately 23+0 weeks of gestation the lower limit for administration of antenatal corticosteroids since only a few primitive alveoli are present below this gestational age. Earlier administration in the 22<sup>nd</sup> week is reasonable if aggressive neonatal intervention is planned after thorough counseling about the limit of viability. (See "[22+6 weeks or less](#)" above and "[23+0 to 33+6 weeks](#)" above.)

- In contemporary obstetric practice in the United States, women delivered at 34+0 to 38+6 weeks of gestation for an obstetric indication are increasingly delivered without amniocentesis to test for fetal lung maturity. The following approach reflects our concern that widespread use of antenatal steroids at  $\geq 34+0$  weeks will result in treatment of many pregnancies that will not benefit or will derive only a modest clinical benefit, while exposing them to the theoretical long-term hazards of steroid administration, particularly adverse neurodevelopment outcome in offspring (see ['34+0 or more weeks'](#) above and ['Potential long-term effects in children and adults'](#) above).
  - For women scheduled for cesarean delivery at 34+0 to 36+6 weeks, we suggest a first course of antenatal corticosteroids (**Grade 2C**). Some clinicians and patients may choose not to use steroids after 34+0 weeks of gestation, given uncertainly in the balance between benefits and risks at  $\geq 34+0$  weeks. Families should be informed regarding potential benefits and risks.
  - For women at 34+0 to 36+6 weeks who have already received a course of antenatal corticosteroids, or who are expected to deliver vaginally, or whose likelihood of delivery within the next seven days is uncertain, we suggest not administering a course of antenatal corticosteroids (**Grade 2C**). Repeat courses of steroids have not been studied at  $\geq 34+0$  weeks, transient tachypnea of the newborn is less common after labor and vaginal birth, and most women with threatened preterm labor do not deliver preterm. This is a controversial area and some national obstetrical organizations have taken a more liberal approach to steroid administration at this gestational age. (See ['Other approaches'](#) above.)
  - We also suggest not administering steroids to women undergoing scheduled cesarean delivery at  $\geq 37+0$  weeks (**Grade 2C**). The overall risk of neonatal respiratory problems at this gestational age is low and illness is rarely serious. Families should be informed regarding potential benefits and risks.
- The absence of consistent and long-term data precludes making a strong recommendation for the number of courses that are safe for the fetus, the appropriate time interval between courses, the optimal dose for repeated courses of therapy, or the full ramifications of the single course approach to therapy. Given the potential for harm from repeated courses of antenatal corticosteroid therapy:
  - We suggest a single course of salvage (rescue, booster) therapy only if the patient is clinically estimated to be at high risk of delivery within the next seven days, more than two weeks have elapsed since the initial course of antenatal corticosteroid therapy, and the gestational age at administration of the initial course was  $\leq 28$  weeks of gestation (**Grade 2C**).
  - We also suggest that providers who elect to give salvage (rescue, booster) therapy use one dose of 12 mg [betamethasone](#) and limit treatment to this one additional dose (**Grade 2C**). One dose appears to be effective and may minimize complications related to steroid use; however, a two dose course is also reasonable. No more than one salvage dose or course is recommended over a single pregnancy. Patients should be informed of potential adverse effects. (See ['Use of repeated courses of therapy'](#) above.)

Use of UpToDate is subject to the [Subscription and License Agreement](#).

## REFERENCES

1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics* 1972; 50:515.
2. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2017; 3:CD004454.
3. Bonanno C, Wapner RJ. Antenatal corticosteroid treatment: what's happened since Drs Liggins and Howie? *Am J Obstet Gynecol* 2009; 200:448.

4. Smolders-de Haas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. *Pediatrics* 1990; 86:65.
5. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. *Am J Obstet Gynecol* 1995; 173:254.
6. Ballard PL. Hormonal regulation of surfactant in fetal life. *Mead Johnson Symp Perinat Dev Med* 1978; :25.
7. Walther FJ, David-Cu R, Mehta EI, et al. Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs. *Am J Physiol* 1996; 271:L187.
8. Polk DH, Ikegami M, Jobe AH, et al. Preterm lung function after retreatment with antenatal betamethasone in preterm lambs. *Am J Obstet Gynecol* 1997; 176:308.
9. Grier DG, Halliday HL. Effects of glucocorticoids on fetal and neonatal lung development. *Treat Respir Med* 2004; 3:295.
10. O'Brodovich HM. Immature epithelial Na<sup>+</sup> channel expression is one of the pathogenetic mechanisms leading to human neonatal respiratory distress syndrome. *Proc Assoc Am Physicians* 1996; 108:345.
11. Vidaeff AC, Ramin SM, Gilstrap LC 3rd, Alcorn JL. In vitro quantification of dexamethasone-induced surfactant protein B expression in human lung cells. *J Matern Fetal Neonatal Med* 2004; 15:155.
12. Bunton TE, Plopper CG. Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque. *Am J Obstet Gynecol* 1984; 148:203.
13. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2006; :CD004454.
14. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. *Am J Obstet Gynecol* 1995; 173:322.
15. Report on the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. U.S. Department of Health and Human Services, Public Health Service, NIH Pub No. 95-3784, November 1994.
16. Smith LM, Altamirano AK, Ervin MG, et al. Prenatal glucocorticoid exposure and postnatal adaptation in premature newborn baboons ventilated for six days. *Am J Obstet Gynecol* 2004; 191:1688.
17. Park CK, Isayama T, McDonald SD. Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2016; 127:715.
18. Travers CP, Carlo WA, McDonald SA, et al. Mortality and pulmonary outcomes of extremely preterm infants exposed to antenatal corticosteroids. *Am J Obstet Gynecol* 2018; 218:130.e1.
19. Raju TN, Mercer BM, Burchfield DJ, Joseph GF Jr. Periviable birth: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Academy of Pediatrics, and American College of Obstetricians and Gynecologists. *Am J Obstet Gynecol* 2014; 210:406.
20. Moore KL, Persaud TVN. The respiratory system. In: *The Developing Human*, 5th ed, WB Saunders, Philadelphia 1993. p.226.
21. Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. *BMJ* 2005; 331:662.
22. Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. *BMJ* 2011; 342:d1696.
23. Althabe F, Belizán JM, McClure EM, et al. A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to

- preterm birth in low-income and middle-income countries: the ACT cluster-randomised trial. *Lancet* 2015; 385:629.
24. Gyamfi-Bannerman C. 1: Antenatal Late Preterm Steroids (ALPS): a randomized trial to reduce neonatal respiratory morbidity. *Am J Obstet Gynecol* 2016; 214:S2.
  25. Stutchfield PR, Whitaker R, Gliddon AE, et al. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). *Arch Dis Child Fetal Neonatal Ed* 2013; 98:F195.
  26. Kolås T, Saugstad OD, Daltveit AK, et al. Planned cesarean versus planned vaginal delivery at term: comparison of newborn infant outcomes. *Am J Obstet Gynecol* 2006; 195:1538.
  27. Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. *Obstet Gynecol* 2001; 97:439.
  28. Tutdibi E, Gries K, Bücheler M, et al. Impact of labor on outcomes in transient tachypnea of the newborn: population-based study. *Pediatrics* 2010; 125:e577.
  29. Saccone G, Berghella V. Antenatal corticosteroids for maturity of term or near term fetuses: systematic review and meta-analysis of randomized controlled trials. *BMJ* 2016; 355:i5044.
  30. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. *N Engl J Med* 2016; 374:1311.
  31. Kemp MW, Newnham JP, Challis JG, et al. The clinical use of corticosteroids in pregnancy. *Hum Reprod Update* 2016; 22:240.
  32. Smith GC, Rowitch D, Mol BW. The role of prenatal steroids at 34-36 weeks of gestation. *Arch Dis Child Fetal Neonatal Ed* 2017; 102:F284.
  33. Kugelman A, Colin AA. Late preterm infants: near term but still in a critical developmental time period. *Pediatrics* 2013; 132:741.
  34. Kinney HC. The near-term (late preterm) human brain and risk for periventricular leukomalacia: a review. *Semin Perinatol* 2006; 30:81.
  35. Chang YP. Evidence for adverse effect of perinatal glucocorticoid use on the developing brain. *Korean J Pediatr* 2014; 57:101.
  36. Champagne DL, de Kloet ER, Joëls M. Fundamental aspects of the impact of glucocorticoids on the (immature) brain. *Semin Fetal Neonatal Med* 2009; 14:136.
  37. Tegethoff M, Pryce C, Meinlschmidt G. Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-adrenal axis function in humans: a systematic review. *Endocr Rev* 2009; 30:753.
  38. Davis EP, Waffarn F, Sandman CA. Prenatal treatment with glucocorticoids sensitizes the hpa axis response to stress among full-term infants. *Dev Psychobiol* 2011; 53:175.
  39. Alexander N, Rosenlöcher F, Dettenborn L, et al. Impact of Antenatal Glucocorticoid Therapy and Risk of Preterm Delivery on Intelligence in Term-Born Children. *J Clin Endocrinol Metab* 2016; 101:581.
  40. Johnson JW, Mitzner W, Beck JC, et al. Long-term effects of betamethasone on fetal development. *Am J Obstet Gynecol* 1981; 141:1053.
  41. Uno H, Lohmiller L, Thieme C, et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. *Brain Res Dev Brain Res* 1990; 53:157.
  42. Shields A, Thomson M, Winter V, et al. Repeated courses of antenatal corticosteroids have adverse effects on aspects of brain development in naturally delivered baboon infants. *Pediatr Res* 2012; 71:661.
  43. Uno H. Unpublished data
  44. Noguchi KK, Walls KC, Wozniak DF, et al. Acute neonatal glucocorticoid exposure produces selective and rapid cerebellar neural progenitor cell apoptotic death. *Cell Death Differ* 2008; 15:1582.



45. Heine VM, Rowitch DH. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2-dependent mechanism. *J Clin Invest* 2009; 119:267.
46. Crudo A, Suderman M, Moisiadis VG, et al. Glucocorticoid programming of the fetal male hippocampal epigenome. *Endocrinology* 2013; 154:1168.
47. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. *Am J Obstet Gynecol* 2016; 215:B13.
48. <http://www.acog.org/About-ACOG/News-Room/Practice-Advisories/Practice-Advisory-Antenatal-Corticosteroid-Administration-in-the-Late-Preterm-Period> (Accessed on April 05, 2016).
49. Committee on Obstetric Practice. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. *Obstet Gynecol* 2017; 130:e102.
50. <https://www.nice.org.uk/guidance/ng25/chapter/Recommendations#maternal-corticosteroids> (Accessed on January 23, 2018).
51. Kamath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH. Antenatal corticosteroids beyond 34 weeks gestation: What do we do now? *Am J Obstet Gynecol* 2016; 215:423.
52. Melamed N, Shah J, Soraisham A, et al. Association Between Antenatal Corticosteroid Administration-to-Birth Interval and Outcomes of Preterm Neonates. *Obstet Gynecol* 2015; 125:1377.
53. Wilms FF, Vis JY, Pattinaja DA, et al. Relationship between the time interval from antenatal corticosteroid administration until preterm birth and the occurrence of respiratory morbidity. *Am J Obstet Gynecol* 2011; 205:49.e1.
54. Waters TP, Mercer B. Impact of timing of antenatal corticosteroid exposure on neonatal outcomes. *J Matern Fetal Neonatal Med* 2009; 22:311.
55. Makhija NK, Tronnes AA, Dunlap BS, et al. Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol. *Am J Obstet Gynecol* 2016; 214:120.e1.
56. Elimian A, Figueroa R, Spitzer AR, et al. Antenatal corticosteroids: are incomplete courses beneficial? *Obstet Gynecol* 2003; 102:352.
57. Norman M, Piedvache A, Børch K, et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort. *JAMA Pediatr* 2017; 171:678.
58. Gross I, Ballard PL, Ballard RA, et al. Corticosteroid stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung: evidence for de novo protein synthesis mediated by glucocorticoid receptors. *Endocrinology* 1983; 112:829.
59. Ikegami M, Polk D, Jobe A. Minimum interval from fetal betamethasone treatment to postnatal lung responses in preterm lambs. *Am J Obstet Gynecol* 1996; 174:1408.
60. Peltoniemi OM, Kari MA, Tammela O, et al. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. *Pediatrics* 2007; 119:290.
61. Brownfoot FC, Gagliardi DI, Bain E, et al. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* 2013; :CD006764.
62. Bar-Lev MR, Maayan-Metzger A, Matok I, et al. Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. *Obstet Gynecol* 2004; 104:484.
63. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. *N Engl J Med* 1999; 341:1190.
64. Walfisch A, Hallak M, Mazor M. Multiple courses of antenatal steroids: risks and benefits. *Obstet Gynecol* 2001; 98:491.

65. Goldenberg RL, Wright LL. Repeated courses of antenatal corticosteroids. *Obstet Gynecol* 2001; 97:316.
66. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. *J Clin Invest* 1975; 56:1548.
67. Hashima JN, Lai Y, Wapner RJ, et al. The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids. *Am J Obstet Gynecol* 2010; 202:263.e1.
68. Gyamfi C, Mele L, Wapner RJ, et al. The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. *Am J Obstet Gynecol* 2010; 203:219.e1.
69. Moore LE, Martin JN Jr. When betamethasone and dexamethasone are unavailable: hydrocortisone. *J Perinatol* 2001; 21:456.
70. Morrison JC, Whybrew WD, Bucovaz ET, Schneider JM. Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. *Am J Obstet Gynecol* 1978; 131:358.
71. Crowther CA, Alfirevic Z, Han S, Haslam RR. Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. *Cochrane Database Syst Rev* 2013; :CD000019.
72. Gonzalez Garay AG, Reveiz L, Velasco Hidalgo L, Solis Galicia C. Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome. *Cochrane Database Syst Rev* 2014; :CD009708.
73. Crowther CA, Crosby DD, Henderson-Smart DJ. Phenobarbital prior to preterm birth for preventing neonatal periventricular haemorrhage. *Cochrane Database Syst Rev* 2010; :CD000164.
74. Crowther CA, Crosby DD, Henderson-Smart DJ. Vitamin K prior to preterm birth for preventing neonatal periventricular haemorrhage. *Cochrane Database Syst Rev* 2010; :CD000229.
75. Verdurmen KM, Renckens J, van Laar JO, Oei SG. The influence of corticosteroids on fetal heart rate variability: a systematic review of the literature. *Obstet Gynecol Surv* 2013; 68:811.
76. Weyrich J, Setter A, Müller A, et al. Longitudinal progression of fetal short-term variation and average acceleration and deceleration capacity after antenatal maternal betamethasone application. *Eur J Obstet Gynecol Reprod Biol* 2017; 212:85.
77. Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. *Am J Obstet Gynecol* 2003; 188:524.
78. Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. *Br J Obstet Gynaecol* 1997; 104:1239.
79. Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. *Br J Obstet Gynaecol* 1998; 105:749.
80. Rotmensch S, Liberati M, Vishne TH, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. *Acta Obstet Gynecol Scand* 1999; 78:493.
81. Rotmensch S, Lev S, Kovo M, et al. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study. *Fetal Diagn Ther* 2005; 20:371.
82. Kelly MK, Schneider EP, Petrikovsky BM, Lesser ML. Effect of antenatal steroid administration on the fetal biophysical profile. *J Clin Ultrasound* 2000; 28:224.
83. Rotmensch S, Liberati M, Celentano C, et al. The effect of betamethasone on fetal biophysical activities and Doppler velocimetry of umbilical and middle cerebral arteries. *Acta Obstet Gynecol Scand* 1999; 78:768.
84. Katz M, Meizner I, Holcberg G, et al. Reduction or cessation of fetal movements after administration of steroids for enhancement of lung maturation. I. Clinical evaluation. *Isr J Med Sci* 1988; 24:5.

85. Lee BH, Stoll BJ, McDonald SA, et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. *Pediatrics* 2006; 117:1503.
86. Schwab M, Coksaygan T, Nathanielsz PW. Betamethasone effects on ovine uterine and umbilical placental perfusion at the dose used to enhance fetal lung maturation. *Am J Obstet Gynecol* 2006; 194:572.
87. Derks JB, Giussani DA, Jenkins SL, et al. A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. *J Physiol* 1997; 499 ( Pt 1):217.
88. Koenen SV, Mecenas CA, Smith GS, et al. Effects of maternal betamethasone administration on fetal and maternal blood pressure and heart rate in the baboon at 0.7 of gestation. *Am J Obstet Gynecol* 2002; 186:812.
89. Smith RP, Miller SL, Igosheva N, et al. Cardiovascular and endocrine responses to cutaneous electrical stimulation after fentanyl in the ovine fetus. *Am J Obstet Gynecol* 2004; 190:836.
90. Miller SL, Supramaniam VG, Jenkin G, et al. Cardiovascular responses to maternal betamethasone administration in the intrauterine growth-restricted ovine fetus. *Am J Obstet Gynecol* 2009; 201:613.e1.
91. Edwards A, Baker LS, Wallace EM. Changes in umbilical artery flow velocity waveforms following maternal administration of betamethasone. *Placenta* 2003; 24:12.
92. Robertson MC, Murila F, Tong S, et al. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. *Obstet Gynecol* 2009; 113:636.
93. Wallace EM, Baker LS. Effect of antenatal betamethasone administration on placental vascular resistance. *Lancet* 1999; 353:1404.
94. Wijnberger LD, Bilardo CM, Hecher K, et al. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. *Ultrasound Obstet Gynecol* 2004; 23:584.
95. Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. *Am J Obstet Gynecol* 2004; 190:296.
96. Banks BA, Cnaan A, Morgan MA, et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. *Am J Obstet Gynecol* 1999; 181:709.
97. Ashwood PJ, Crowther CA, Willson KJ, et al. Neonatal adrenal function after repeat dose prenatal corticosteroids: a randomized controlled trial. *Am J Obstet Gynecol* 2006; 194:861.
98. Davis EP, Townsend EL, Gunnar MR, et al. Effects of prenatal betamethasone exposure on regulation of stress physiology in healthy premature infants. *Psychoneuroendocrinology* 2004; 29:1028.
99. Schäffer L, Luzi F, Burkhardt T, et al. Antenatal betamethasone administration alters stress physiology in healthy neonates. *Obstet Gynecol* 2009; 113:1082.
100. Waffarn F, Davis EP. Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. *Am J Obstet Gynecol* 2012; 207:446.
101. Sotiriadis A, Tsiami A, Papatheodorou S, et al. Neurodevelopmental Outcome After a Single Course of Antenatal Steroids in Children Born Preterm: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2015; 125:1385.
102. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. *BMJ* 2005; 331:665.

103. Benediktsson R, Lindsay RS, Noble J, et al. Glucocorticoid exposure in utero: new model for adult hypertension. *Lancet* 1993; 341:339.
104. Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet* 2005; 365:1856.
105. Alexander N, Rosenlöcher F, Stalder T, et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. *J Clin Endocrinol Metab* 2012; 97:3538.
106. Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. *Pediatrics* 2012; 129:e1282.
107. McKinlay CJ, Cutfield WS, Battin MR, et al. Cardiovascular risk factors in children after repeat doses of antenatal glucocorticoids: an RCT. *Pediatrics* 2015; 135:e405.
108. Anwar MA, Saleh AI, Al Olabi R, et al. Glucocorticoid-induced fetal origins of adult hypertension: Association with epigenetic events. *Vascul Pharmacol* 2016; 82:41.
109. Seckl JR. Prenatal glucocorticoids and long-term programming. *Eur J Endocrinol* 2004; 151 Suppl 3:U49.
110. Stubblefield PG. Pulmonary edema occurring after therapy with dexamethasone and terbutaline for premature labor: a case report. *Am J Obstet Gynecol* 1978; 132:341.
111. Ogburn PL Jr, Julian TM, Williams PP, Thompson TR. The use of magnesium sulfate for tocolysis in preterm labor complicated by twin gestation and betamimetic-induced pulmonary edema. *Acta Obstet Gynecol Scand* 1986; 65:793.
112. Ogunyemi D. Risk factors for acute pulmonary edema in preterm delivery. *Eur J Obstet Gynecol Reprod Biol* 2007; 133:143.
113. Amorim MM, Santos LC, Faúndes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. *Am J Obstet Gynecol* 1999; 180:1283.
114. Mastrobattista JM, Patel N, Monga M. Betamethasone alteration of the one-hour glucose challenge test in pregnancy. *J Reprod Med* 2001; 46:83.
115. Gurbuz A, Karateke A, Ozturk G, Kabaca C. Is 1-hour glucose screening test reliable after a short-term administration of antenatal betamethasone? *Am J Perinatol* 2004; 21:415.
116. Vaisbuch E, Levy R, Hagay Z. The effect of betamethasone administration to pregnant women on maternal serum indicators of infection. *J Perinat Med* 2002; 30:287.
117. Kadanali S, Ingeç M, Küçüközkan T, et al. Changes in leukocyte, granulocyte and lymphocyte counts following antenatal betamethasone administration to pregnant women. *Int J Gynaecol Obstet* 1997; 58:269.
118. Zephyrin LC, Hong KN, Wapner RJ, et al. Gestational age-specific risks vs benefits of multicourse antenatal corticosteroids for preterm labor. *Am J Obstet Gynecol* 2013; 209:330.e1.
119. Crowther CA, Haslam RR, Hiller JE, et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. *Lancet* 2006; 367:1913.
120. Practice Bulletin No. 159: Management of Preterm Labor. *Obstet Gynecol* 2016; 127:e29.
121. Garite TJ, Kurtzman J, Maurel K, et al. Impact of a 'rescue course' of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. *Am J Obstet Gynecol* 2009; 200:248.e1.
122. McEvoy C, Schilling D, Peters D, et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. *Am J Obstet Gynecol* 2010; 202:544.e1.
123. Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. *Cochrane Database Syst Rev* 2015; :CD003935.

124. Crowther CA, Anderson PJ, McKinlay CJ, et al. Mid-Childhood Outcomes of Repeat Antenatal Corticosteroids: A Randomized Controlled Trial. *Pediatrics* 2016; 138.
125. McKinlay CJD, Cutfield WS, Battin MR, et al. Mid-Childhood Bone Mass After Exposure to Repeat Doses of Antenatal Glucocorticoids: A Randomized Trial. *Pediatrics* 2017; 139.
126. Wapner RJ, Sorokin Y, Thom EA, et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. *Am J Obstet Gynecol* 2006; 195:633.
127. Sawady J, Mercer BM, Wapner RJ, et al. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. *Am J Obstet Gynecol* 2007; 197:281.e1.
128. Murphy KE, Willan AR, Hannah ME, et al. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. *Obstet Gynecol* 2012; 119:917.
129. Murphy KE, Hannah ME, Willan AR, et al. Maternal side-effects after multiple courses of antenatal corticosteroids (MACS): the three-month follow-up of women in the randomized controlled trial of MACS for preterm birth study. *J Obstet Gynaecol Can* 2011; 33:909.
130. Asztalos EV, Murphy KE, Willan AR, et al. Multiple courses of antenatal corticosteroids for preterm birth study: outcomes in children at 5 years of age (MACS-5). *JAMA Pediatr* 2013; 167:1102.
131. Stålnacke J, Diaz Heijtz R, Norberg H, et al. Cognitive outcome in adolescents and young adults after repeat courses of antenatal corticosteroids. *J Pediatr* 2013; 163:441.
132. Braun T, Challis JR, Newnham JP, Sloboda DM. Early-life glucocorticoid exposure: the hypothalamic-pituitary-adrenal axis, placental function, and long-term disease risk. *Endocr Rev* 2013; 34:885.
133. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: size at birth and subsequent development. *Am J Obstet Gynecol* 1999; 180:114.
134. Huang WL, Beazley LD, Quinlivan JA, et al. Effect of corticosteroids on brain growth in fetal sheep. *Obstet Gynecol* 1999; 94:213.
135. Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 1: Outcomes. *Nat Rev Endocrinol* 2014; 10:391.
136. Howie RN, Liggins GC. The New Zealand study of antepartum glucocorticoid treatment. In: Lung development: biological and clinical perspectives, Farrell PM (Ed), Academic Press, New York 1983. Vol 2, p.255.
137. Ballard PL. Hormones and lung maturation. In: Monographs on Endocrinology, Springer-Verlag, Berlin 1986. Vol 28, p.1.
138. Ballard PL, Ballard RA. Glucocorticoid receptors and the role of glucocorticoids in fetal lung development. *Proc Natl Acad Sci U S A* 1972; 69:2668.
139. Oakley RH, Cidlowski JA. Homologous down regulation of the glucocorticoid receptor: the molecular machinery. *Crit Rev Eukaryot Gene Expr* 1993; 3:63.
140. Khandelwal M, Chang E, Hansen C, et al. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. *Am J Obstet Gynecol* 2012; 206:201.e1.
141. Haas DM, McCullough W, McNamara MF, Olsen C. The first 48 hours: Comparing 12-hour and 24-hour betamethasone dosing when preterm deliveries occur rapidly. *J Matern Fetal Neonatal Med* 2006; 19:365.
142. Egerman RS, Mercer BM, Doss JL, Sibai BM. A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. *Am J Obstet Gynecol* 1998; 179:1120.
143. Spellacy WN, Buhi WC, Riggall FC, Holsinger KL. Human amniotic fluid lecithin-sphingomyelin ratio changes with estrogen or glucocorticoid treatment. *Am J Obstet Gynecol* 1973; 115:216.

144. Piazzze JJ, Maranghi L, Nigro G, et al. The effect of glucocorticoid therapy on fetal lung maturity indices in hypertensive pregnancies. *Obstet Gynecol* 1998; 92:220.
145. Shanks A, Gross G, Shim T, et al. Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. *Am J Obstet Gynecol* 2010; 203:47.e1.
146. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. *Am J Obstet Gynecol* 1981; 141:276.
147. Farrell PM, Engle MJ, Zachman RD, et al. Amniotic fluid phospholipids after maternal administration of dexamethasone. *Am J Obstet Gynecol* 1983; 145:484.
148. Della Torre M, Hibbard JU, Jeong H, Fischer JH. Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. *Am J Obstet Gynecol* 2010; 203:254.e1.
149. Hashimoto LN, Hornung RW, Lindsell CJ, et al. Effects of antenatal glucocorticoids on outcomes of very low birth weight multifetal gestations. *Am J Obstet Gynecol* 2002; 187:804.
150. Blickstein I, Shinwell ES, Lusk A, et al. Plurality-dependent risk of respiratory distress syndrome among very-low-birth-weight infants and antepartum corticosteroid treatment. *Am J Obstet Gynecol* 2005; 192:360.
151. Blickstein I, Reichman B, Lusk A, et al. Plurality-dependent risk of severe intraventricular hemorrhage among very low birth weight infants and antepartum corticosteroid treatment. *Am J Obstet Gynecol* 2006; 194:1329.
152. Viteri OA, Blackwell SC, Chauhan SP, et al. Antenatal Corticosteroids for the Prevention of Respiratory Distress Syndrome in Premature Twins. *Obstet Gynecol* 2016; 128:583.
153. Melamed N, Shah J, Yoon EW, et al. The role of antenatal corticosteroids in twin pregnancies complicated by preterm birth. *Am J Obstet Gynecol* 2016; 215:482.e1.
154. Committee on Practice Bulletins—Obstetrics, Society for Maternal–Fetal Medicine. Practice Bulletin No. 169: Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies. *Obstet Gynecol* 2016; 128:e131.
155. Amiya RM, Mlunde LB, Ota E, et al. Antenatal Corticosteroids for Reducing Adverse Maternal and Child Outcomes in Special Populations of Women at Risk of Imminent Preterm Birth: A Systematic Review and Meta-Analysis. *PLoS One* 2016; 11:e0147604.
156. Andrews EB, Marcucci G, White A, Long W. Associations between use of antenatal corticosteroids and neonatal outcomes within the Exosurf Neonatal Treatment Investigational New Drug Program. *Am J Obstet Gynecol* 1995; 173:290.

Topic 6796 Version 84.0

## Contributor Disclosures

**Men-Jean Lee, MD** Nothing to disclose **Debra Guinn, MD, FACOG** Nothing to disclose **Charles J Lockwood, MD, MHCM** Nothing to disclose **Richard Martin, MD** Consultant/Advisory Boards: Windtree Therapeutics [Surfactant Inhalation Trial]; CareFusion in Automated Oxygenation Control Trial [STAMINA Trial]. **Vanessa A Barss, MD, FACOG** Nothing to disclose

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy](#)